eyeQ: Burberry, M&G, Shell, Thermo Fisher Scientific
Experts at eyeQ use AI and their own smart machine to generate actionable trading signals for 10 UK shares and 10 overseas stocks. All are either cheap or expensive given current macro conditions.
3rd August 2026 10:50
by Huw Roberts from eyeQ
“Our signals are crafted through macro-valuation, trend analysis, and meticulous back-testing. This combination ensures a comprehensive evaluation of an asset's value, market conditions, and historical performance.” eyeQ
- Discover: eyeQ analysis explained | eyeQ: our smart machine in action | Glossary
This series of weekly articles uses eyeQ’s smart machine to highlight 10 stocks whose share price trades at either a discount or premium to eyeQ’s Model Value price (where macro conditions say the share 'should’ trade).
A minus figure in these tables indicates a share trading below eyeQ’s Model Value, implying they are ‘cheap’ versus macro conditions. A plus figure screens as rich because the current share price is above eyeQ’s Model Value.
All companies must have a model relevance above 65%, which means the macro environment is critical and any valuation signals carry strong weight.
Here are definitions of terms used in the analysis:
Model value
Where our smart machine calculates that any stock market index, single stock or exchange-traded fund (ETF) should be priced (the fair value) given the overall macroeconomic environment.
Model relevance
How confident we are in the model value. The higher the number the better! Above 65% means the macro environment is critical, so any valuation signals carry strong weight. Below 65%, we deem that something other than macro is driving the price.
Fair Value Gap (FVG)
The difference between our model value (fair value) and where the price currently is. A positive Fair Value Gap means the security is above the model value, which we refer to as “rich”. A negative FVG means that it's cheap. The bigger the FVG, the bigger the dislocation and therefore a better entry level for trades.
Long Term model
This model looks at share prices over the last 12 months, captures the company’s relationship with growth, inflation, currency shifts, central bank policy etc and calculates our key results - model value, model relevance, Fair Value Gap.
UK Top 10
| Company | Macro Relevance | Model Value | Fair Value Gap |
| St James's Place (LSE:STJ) | 79 | 1102.15p | -4.62% |
| Antofagasta (LSE:ANTO) | 74 | 3759.52p | -2.86% |
| M&G Ordinary Shares (LSE:MNG) | 79 | 364.77p | -2.03% |
| Barclays (LSE:BARC) | 85 | 513.82p | -1.01% |
| Pearson (LSE:PSON) | 78 | 1266.98p | -0.79% |
| Imperial Brands (LSE:IMB) | 69 | 2672.19p | 5.41% |
| Shell (LSE:SHEL) | 77 | 3152.67p | 6.82% |
| Smith & Nephew (LSE:SN.) | 73 | 1071.74p | 7.49% |
| Informa (LSE:INF) | 78 | 815.84p | 7.9% |
| Burberry Group (LSE:BRBY) | 79 | 1076.26p | 9.37% |
Source: eyeQ. Long Term strategic models. Data correct as at 31 July 2026.
Burberry
Burberry Group (LSE:BRBY) sits 10.5% above eyeQ model value of 1,088.39p - that’s 9.4% rich, the biggest fair value gap in this week’s UK list and the biggest fair value gap in a year. The surge in the share price is a result of stronger trading results, building confidence that the company is finally managing to turn a corner after years of poor performance. But also, big institutions are circling the stock. Both Frasers Groupand Norges Bank (Norway’s sovereign wealth fund) have increased their stakes, adding to the idea that the company is indeed starting to recover.
The interest of long-term players with deep pockets is undoubtedly a good sign. eyeQ, however, is warning that the recent rally has run ahead of macro fundamentals. The former may mean you disregard a systematic bearish signal, but the message from our model is that these aren’t great levels to chase.
International Top 10
| Company | Macro Relevance | Model Value | Fair Value Gap |
| Gilead Sciences Inc (NASDAQ:GILD) | 69 | 132.30 | -1.61% |
| Ferrovial NV (EURONEXT:FER) | 70 | 57.62 | -1.55% |
| Zurich Insurance Group AG (SIX:ZURN) | 71 | 624.57 | -1.42% |
| The Walt Disney Co (NYSE:DIS) | 81 | 97.13 | -0.98% |
| Lowe's Companies Inc (NYSE:LOW) | 70 | 207.91 | -0.05% |
| Airbus SE (EURONEXT:AIR) | 75 | 186.63 | 7.7% |
| Nike Inc Class B (NYSE:NKE) | 79 | 38.23 | 8.34% |
| Medtronic (NYSE:MDT) | 83 | 77.62 | 9.11% |
| SoFi Technologies Inc Ordinary Shares (NASDAQ:SOFI) | 81 | 14.70 | 9.87% |
| Thermo Fisher Scientific Inc (NYSE:TMO) | 68 | 517.17 | 9.95% |
Source: eyeQ. Long Term strategic models. Data correct as at 31 July 2026.
Thermo Fisher Scientific
Strong Q2 earnings were the catalyst for a bounce in the life sciences company. The sector is hot right now with many investors viewing it as an area that will benefit from artificial intelligence (AI). So, encouraging news at the company level means there are two tailwinds.
Sadly, the third, top-down tailwind is missing. eyeQ model value is flatlining in the low $500 area. Macro doesn’t yet support additional upside. Indeed, the stock has run ahead of big picture forces like economic growth and inflation. It’s almost 10% rich to eyeQ model value, which is enough to trigger a new bearish signal.
These third-party research articles are provided by eyeQ (Quant Insight). interactive investor does not make any representation as to the completeness, accuracy or timeliness of the information provided, nor do we accept any liability for any losses, costs, liabilities or expenses that may arise directly or indirectly from your use of, or reliance on, the information (except where we have acted negligently, fraudulently or in wilful default in relation to the production or distribution of the information).
The value of your investments may go down as well as up. You may not get back all the money that you invest.
Equity research is provided for information purposes only. Neither eyeQ (Quant Insight) nor interactive investor have considered your personal circumstances, and the information provided should not be considered a personal recommendation. If you are in any doubt as to the action you should take, please consult an authorised financial adviser.
Disclosure
We use a combination of fundamental and technical analysis in forming our view as to the valuation and prospects of an investment. Where relevant we have set out those particular matters we think are important in the above article, but further detail can be found here.
Please note that our article on this investment should not be considered to be a regular publication.
Details of all recommendations issued by ii during the previous 12-month period can be found here.
ii adheres to a strict code of conduct. Contributors may hold shares or have other interests in companies included in these portfolios, which could create a conflict of interests. Contributors intending to write about any financial instruments in which they have an interest are required to disclose such interest to ii and in the article itself. ii will at all times consider whether such interest impairs the objectivity of the recommendation.
In addition, individuals involved in the production of investment articles are subject to a personal account dealing restriction, which prevents them from placing a transaction in the specified instrument(s) for a period before and for five working days after such publication. This is to avoid personal interests conflicting with the interests of the recipients of those investment articles.